MedPath

Safety and usefulness of application of direct painless electrical current to brain in patients with pseudo seizure.

Not Applicable
Conditions
Health Condition 1: F445- Conversion disorder with seizuresor convulsions
Registration Number
CTRI/2020/09/027669
Lead Sponsor
JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION amp RESEARCH PUDUCHERRY
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Our study include two sets of patients i.e

1.clinically established PNES &;

2.Documented PNES,

having aged >18 years and >=2 events/month.

According to ILAE (International League Against Epilepsy),

Clinically Established PNES:These are those patients, who are diagnosed by an experienced clinician(in seizure disorder) on the basis of video or person that showing semiology typical of PNES.

Documented PNES are those patients diagnosed by experienced clinician on the basis of semiology typical of PNES in video EEG.

Exclusion Criteria

1.Subjects with known epilepsy

2.Subjects with PNES who have significant intellectual disability

3.Severe psychiatric comorbidity and suicidal ideations

4.Pregnant women

5.Those with dementia, psychosis, delirium, scalp infections or lesions

6.Subjects with history of brain surgery or aneurysm clipping or electrical device implantation like pacemaker

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To determine the efficacy of transcranial direct current stimulation compared to sham stimulation in increasing the proportion of subjects achieving â?¥50% reduction in event frequency/month at the end of 1st month of treatment compared to baseline in subjects with psychogenic non epileptic seizuresTimepoint: 1 month
Secondary Outcome Measures
NameTimeMethod
1.To determine the safety of tDCS in this subject population. <br/ ><br>2.To determine if the effects of tDCS on event frequency at the end of 2nd and 3rd month after treatment. <br/ ><br>3.To determine effects of tDCS on measures of psychopathology (HAM-A and HAM-D) and quality of life measures (WHO BREF-QOL and QOLIE) <br/ ><br>4.To explore factors associated with response to tDCS such as imaging abnormalities <br/ ><br>5.To see the effect of tDCS on the EEG power spectrum <br/ ><br>Timepoint: 2nd & 3rd month
© Copyright 2025. All Rights Reserved by MedPath